Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells $285,899.13 in Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. The trade was a 1.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

TG Therapeutics Stock Up 2.8 %

NASDAQ TGTX opened at $28.77 on Friday. The business has a fifty day moving average price of $31.45 and a 200 day moving average price of $25.28. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market cap of $4.48 billion, a P/E ratio of -287.67 and a beta of 2.24. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. TG Therapeutics’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.73 EPS. Research analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on TGTX shares. The Goldman Sachs Group lifted their price target on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their target price on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. TD Cowen initiated coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright upped their price objective on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, StockNews.com upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.67.

Institutional Trading of TG Therapeutics

A number of hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC boosted its holdings in shares of TG Therapeutics by 562.4% during the 4th quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company’s stock worth $77,000 after purchasing an additional 2,171 shares during the last quarter. JPMorgan Chase & Co. lifted its position in TG Therapeutics by 60.0% during the third quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company’s stock worth $16,859,000 after buying an additional 270,286 shares in the last quarter. Principal Financial Group Inc. boosted its stake in TG Therapeutics by 1,549.4% during the third quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock worth $18,061,000 after buying an additional 725,371 shares during the last quarter. Franklin Resources Inc. grew its holdings in TG Therapeutics by 3.8% in the 3rd quarter. Franklin Resources Inc. now owns 128,985 shares of the biopharmaceutical company’s stock valued at $2,945,000 after buying an additional 4,756 shares in the last quarter. Finally, Synovus Financial Corp purchased a new position in shares of TG Therapeutics during the 3rd quarter worth $465,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.